Minimum 2:1 (or equivalent).
Months of entry
Emerging life science technologies and innovations have the potential to revolutionise healthcare and improve human welfare in developing countries. A key barrier to entry for these emerging technologies is understanding the complexity of the innovation process – not only the factors influencing product development, but also issues of access, procurement and capacity within the health system.
Our research in the Development and Policy Practice Group (DPP), embedded in multi-disciplinary and novel social science approaches, seeks to shed some light on how appropriate innovations and capacities can emerge and spread, become embedded in and influence health systems, but overall how they can be measured and evaluated in light of the envisaged affordable and equitable access to high- quality health care.
We have had a number of externally and internally funded research projects, including:
- Pharmaceutical sector standards in developing countries.
- Medical device industries in emerging economies.
- Innovative spending in Global health.
- Bio economy, pharmaceuticals and the global economy..
- Professor Joanna Chataway
- Dr Rebecca Hanlin
- Dr Dinar Kale
- Dr Julius Mugwagwa
- Professor David Wield
Health product development partnerships and beyond Procurement as a policy tool for local innovation Inclusive industrial innovation for local LMIC health strengthening Global health governance and regulations Technological capability development in healthcare industries based in developing countries
Fees and funding
Please visit our website for information on: Fees and funding
Qualification and course duration
Course contact details
- Dr Sue Oreszczyn
- +44 (0)1908 332940